Literature DB >> 35158782

NOX2-Induced High Glycolytic Activity Contributes to the Gain of COL5A1-Mediated Mesenchymal Phenotype in GBM.

Youngjoon Park1, Minwoo Park2, Junhyung Kim2, Juwon Ahn1, Jeongmin Sim1, Ji-In Bang3, Jinhyung Heo4, Hyejeong Choi5, Kyunggi Cho1, Mihye Lee2, Jong-Seok Moon2, Jaejoon Lim1.   

Abstract

The alteration of the cellular metabolism is a hallmark of glioma. The high glycolytic phenotype is a critical factor in the pathogenesis of high-grade glioma, including glioblastoma multiforme (GBM). GBM has been stratified into three subtypes as the proneural, mesenchymal, and classical subtypes. High glycolytic activity was found in mesenchymal GBM relative to proneural GBM. NADPH oxidase 2 (NOX2) has been linked to cellular metabolism and epithelial-mesenchymal transition (EMT) in tumors. The role of NOX2 in the regulation of the high glycolytic phenotype and the gain of the mesenchymal subtype in glioma remain unclear. Here, our results show that the levels of NOX2 were elevated in patients with GBM. NOX2 induces hexokinase 2 (HK2)-dependent high glycolytic activity in U87MG glioma cells. High levels of NOX2 are correlated with high levels of HK2 and glucose uptake in patients with GBM relative to benign glioma. Moreover, NOX2 increases the expression of mesenchymal-subtype-related genes, including COL5A1 and FN1 in U87MG glioma cells. High levels of NOX2 are correlated with high levels of COL5A1 and the accumulation of extracellular matrix (ECM) in patients with GBM relative to benign glioma. Furthermore, high levels of HK2 are correlated with high levels of COL5A1 in patients with GBM relative to benign glioma. Our results suggest that NOX2-induced high glycolytic activity contributes to the gain of the COL5A1-mediated mesenchymal phenotype in GBM.

Entities:  

Keywords:  COL5A1; GBM; NOX2; glycolysis; mesenchymal phenotype

Year:  2022        PMID: 35158782      PMCID: PMC8833670          DOI: 10.3390/cancers14030516

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  39 in total

Review 1.  Insights into molecular therapy of glioma: current challenges and next generation blueprint.

Authors:  Y Rajesh; Ipsita Pal; Payel Banik; Sandipan Chakraborty; Sachin A Borkar; Goutam Dey; Ahona Mukherjee; Mahitosh Mandal
Journal:  Acta Pharmacol Sin       Date:  2017-03-20       Impact factor: 6.150

2.  Glucose withdrawal induces oxidative stress followed by apoptosis in glioblastoma cells but not in normal human astrocytes.

Authors:  Nannette Jelluma; Xiaodong Yang; David Stokoe; Gerard I Evan; Tobias B Dansen; Daphne A Haas-Kogan
Journal:  Mol Cancer Res       Date:  2006-05       Impact factor: 5.852

3.  EBV-encoded EBNA1 regulates cell viability by modulating miR34a-NOX2-ROS signaling in gastric cancer cells.

Authors:  Seung-Mi Kim; Dae Young Hur; Seung-Woo Hong; Ji Hyun Kim
Journal:  Biochem Biophys Res Commun       Date:  2017-10-20       Impact factor: 3.575

4.  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.

Authors:  Roel G W Verhaak; Katherine A Hoadley; Elizabeth Purdom; Victoria Wang; Yuan Qi; Matthew D Wilkerson; C Ryan Miller; Li Ding; Todd Golub; Jill P Mesirov; Gabriele Alexe; Michael Lawrence; Michael O'Kelly; Pablo Tamayo; Barbara A Weir; Stacey Gabriel; Wendy Winckler; Supriya Gupta; Lakshmi Jakkula; Heidi S Feiler; J Graeme Hodgson; C David James; Jann N Sarkaria; Cameron Brennan; Ari Kahn; Paul T Spellman; Richard K Wilson; Terence P Speed; Joe W Gray; Matthew Meyerson; Gad Getz; Charles M Perou; D Neil Hayes
Journal:  Cancer Cell       Date:  2010-01-19       Impact factor: 31.743

5.  Cancer statistics, 2013.

Authors:  Rebecca Siegel; Deepa Naishadham; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2013-01-17       Impact factor: 508.702

Review 6.  Ionizing radiation and the risk of brain and central nervous system tumors: a systematic review.

Authors:  Melissa Z Braganza; Cari M Kitahara; Amy Berrington de González; Peter D Inskip; Kimberly J Johnson; Preetha Rajaraman
Journal:  Neuro Oncol       Date:  2012-09-05       Impact factor: 12.300

Review 7.  Altered cellular metabolism in gliomas - an emerging landscape of actionable co-dependency targets.

Authors:  Junfeng Bi; Sudhir Chowdhry; Sihan Wu; Wenjing Zhang; Kenta Masui; Paul S Mischel
Journal:  Nat Rev Cancer       Date:  2019-12-05       Impact factor: 69.800

8.  CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013-2017.

Authors:  Quinn T Ostrom; Nirav Patil; Gino Cioffi; Kristin Waite; Carol Kruchko; Jill S Barnholtz-Sloan
Journal:  Neuro Oncol       Date:  2020-10-30       Impact factor: 12.300

Review 9.  Theranostic Nanomedicine for Malignant Gliomas.

Authors:  Michele d'Angelo; Vanessa Castelli; Elisabetta Benedetti; Andrea Antonosante; Mariano Catanesi; Reyes Dominguez-Benot; Giuseppina Pitari; Rodolfo Ippoliti; Annamaria Cimini
Journal:  Front Bioeng Biotechnol       Date:  2019-11-14
View more
  2 in total

1.  Next-Generation Grade and Survival Expression Biomarkers of Human Gliomas Based on Algorithmically Reconstructed Molecular Pathways.

Authors:  Marianna A Zolotovskaia; Max A Kovalenko; Victor S Tkachev; Alexander M Simonov; Maxim I Sorokin; Ella Kim; Denis V Kuzmin; Betul Karademir-Yilmaz; Anton A Buzdin
Journal:  Int J Mol Sci       Date:  2022-06-30       Impact factor: 6.208

2.  Glioblastoma Multiforme Selective Nanomedicines for Improved Anti-Cancer Treatments.

Authors:  Jason Thomas Duskey; Arianna Rinaldi; Ilaria Ottonelli; Riccardo Caraffi; Chiara Alessia De Benedictis; Ann Katrin Sauer; Giovanni Tosi; Maria Angela Vandelli; Barbara Ruozi; Andreas Martin Grabrucker
Journal:  Pharmaceutics       Date:  2022-07-12       Impact factor: 6.525

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.